Neumora Therapeutics, Inc.
490 Arsenal Way, Suite 200
Watertown, Massachusetts 02472
September 12, 2023
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
| Attention: | Eric Atallah | |
| Al Pavot | ||
| Daniel Crawford | ||
| Laura Crotty | ||
| Re: | Neumora Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333- 274229) | |
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (Registration No. 333-274229) (the “Registration Statement”) of Neumora Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 14, 2023, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Phillip Stoup at (415) 395-8216 or B. Shayne Kennedy at (714) 755-8181.
Thank you for your assistance in this matter.
| Very truly yours, | ||
| NEUMORA THERAPEUTICS, INC. | ||
| By: | /s/ Henry O. Gosebruch | |
| Henry O. Gosebruch | ||
| President and Chief Executive Officer | ||
| cc: | Paul L. Berns, Neumora Therapeutics, Inc. | |
| Phillip Stoup, Latham & Watkins LLP | ||
| B. Shayne Kennedy, Latham & Watkins LLP | ||
| Charles S. Kim, Cooley LLP | ||
| Kristin VanderPas, Cooley LLP | ||
| Dave Peinsipp, Cooley LLP | ||
| Denny Won, Cooley LLP |